Lifecore Biomedical (LFCR) director awarded 25,907 RSUs

Rhea-AI Filing Summary

Lifecore Biomedical director Jason Aryeh received an equity award of 25,907 shares of common stock as a grant, not an open-market purchase. The award reflects restricted stock units that convert into common stock on a 1-for-1 basis. Following this grant, he directly holds 69,967 shares. The units vest on the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders, provided that meeting occurs at least 50 weeks after June 4, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aryeh Jason

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	--

Holdings After Transaction: Common Stock — 69,967 shares (Direct, null)

Footnotes (1)

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

Shares granted: 25,907 shares Price per share: $0.00 per share Post-transaction holdings: 69,967 shares +2 more

5 metrics

Shares granted 25,907 shares Grant of common stock (via RSUs) to director Aryeh

Price per share $0.00 per share Compensation grant, not open-market purchase

Post-transaction holdings 69,967 shares Total common stock directly held after grant

Conversion ratio 1-for-1 Each restricted stock unit converts into one common share

Vesting date June 4, 2027 Earlier of this date or 2027 annual meeting, with 50-week condition

Key Terms

restricted stock units, 1 for 1 basis, vests, annual meeting of stockholders

4 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

1 for 1 basis financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

vests financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

annual meeting of stockholders financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aryeh Jason

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MINNESOTA 55318

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		25,907	A	(1)(2)	69,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Jason Aryeh	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Lifecore Biomedical (LFCR) director Jason Aryeh report on this Form 4?

He reported receiving a grant of 25,907 shares of common stock as compensation. The award is structured as restricted stock units that convert into common stock on a 1-for-1 basis, increasing his direct holdings to 69,967 shares after the transaction.

Is Jason Aryeh’s Lifecore (LFCR) transaction a stock purchase or a grant?

It is a grant, not a purchase. The Form 4 shows transaction code A, described as a grant, award, or other acquisition, with a price per share of $0.00, indicating compensation rather than an open-market buy of Lifecore Biomedical stock.

How many Lifecore Biomedical (LFCR) shares does Jason Aryeh hold after this grant?

After the grant, he directly holds 69,967 shares of Lifecore Biomedical common stock. This figure includes the newly granted 25,907 shares reported in the Form 4 and shows his total direct ownership position immediately following the award.

When do Jason Aryeh’s Lifecore Biomedical (LFCR) restricted stock units vest?

They vest on the earlier of June 4, 2027 or the date of the 2027 annual meeting of stockholders. The meeting date must be at least 50 weeks after June 4, 2026, as specified in the vesting footnote to the Form 4 filing.

What does 1-for-1 conversion mean for Lifecore (LFCR) restricted stock units?

It means each restricted stock unit converts into one share of Lifecore Biomedical common stock. The Form 4 footnote states the restricted stock units convert on a 1-for-1 basis, directly linking the number of units granted to the same number of common shares.